KSAC, a defined Leishmania antigen, plus adjuvant protects against the virulence of L. major transmitted by its natural vector Phlebotomus duboscqi

PLoS Neglected Tropical Diseases

Volumn 6, Issue 4, 2012, Pages

  Gomes, Regis ^a   Teixeira, Clarissa ^a   Oliveira, Fabiano ^a   Lawyer, Phillip G ^a   Elnaiem, Dia Eldin ^b   Meneses, Claudio ^a   Goto, Yasuyuki ^c,d   Bhatia, Ajay ^c   Howard, Randall F ^c   Reed, Steven G ^c   Valenzuela, Jesus G ^a   Kamhawi, Shaden ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b Eastern Shore University   (United States)

^c INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 10; INTERLEUKIN 4; LEISHMANIA VACCINE; LEISHMANIA VACCINE KSAC; LEISHMANIA VACCINE L110F; UNCLASSIFIED DRUG; IMMUNOLOGICAL ADJUVANT; PARASITE ANTIGEN; PROTOZOON ANTIBODY;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; EAR INJURY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; LEISHMANIA MAJOR; LEISHMANIASIS; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PARASITE LOAD; PARASITE TRANSMISSION; PARASITE VIRULENCE; REAL TIME POLYMERASE CHAIN REACTION; VACCINATION; ANIMAL; BAGG ALBINO MOUSE; BLOOD; DISEASE MODEL; DISEASE TRANSMISSION; IMMUNOLOGY; PARASITOLOGY; PATHOLOGY; PHLEBOTOMUS; SECRETION; SKIN LEISHMANIASIS; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; DISEASE MODELS, ANIMAL; FEMALE; INTERFERON-GAMMA; LEISHMANIA MAJOR; LEISHMANIASIS VACCINES; LEISHMANIASIS, CUTANEOUS; MICE; MICE, INBRED BALB C; PARASITE LOAD; PHLEBOTOMUS; T-LYMPHOCYTES;

EID: 84861204189     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0001610     Document Type: Article

References (34)

1. WHO (2010) WHO Technical Report Series.
2. Desjeux P, (2004) Leishmaniasis. Nat Rev Microbiol 2: 692.
3. Belkaid Y, Hoffmann KF, Mendez S, Kamhawi S, Udey MC, et al. (2001) The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J Exp Med 194: 1497-1506.
4. Greenblatt CL, (1980) The present and future of vaccination for cutaneous leishmaniasis. Prog Clin Biol Res 47: 259-285.
5. Nadim A, Javadian E, Tahvildar-Bidruni G, Ghorbani M, (1983) Effectiveness of leishmanization in the control of cutaneous leishmaniasis. Bull Soc Pathol Exot Filiales 76: 377-383.
6. Handman E, (2001) Leishmaniasis: current status of vaccine development. Clin Microbiol Rev 14: 229-243.
7. Uzonna JE, Wei G, Yurkowski D, Bretscher P, (2001) Immune elimination of Leishmania major in mice: implications for immune memory, vaccination, and reactivation disease. J Immunol 167: 6967-6974.
8. Costa CH, Peters NC, Maruyama SR, de Brito EC Jr, Santos IK, (2011) Vaccines for the leishmaniases: proposals for a research agenda. PLoS Negl Trop Dis 5: e943.
9. Rogers ME, Sizova OV, Ferguson MA, Nikolaev AV, Bates PA, (2006) Synthetic glycovaccine protects against the bite of leishmania-infected sand flies. J Infect Dis 194: 512-518.
10. Peters NC, Kimblin N, Secundino N, Kamhawi S, Lawyer P, et al. (2009) Vector transmission of leishmania abrogates vaccine-induced protective immunity. PLoS Pathog 5: e1000484.
11. Bertholet S, Goto Y, Carter L, Bhatia A, Howard RF, et al. (2009) Optimized subunit vaccine protects against experimental leishmaniasis. Vaccine 27: 7036-7045.
12. Goto Y, Bhatia A, Raman VS, Liang H, Mohamath R, et al. (2011) KSAC, the first defined polyprotein vaccine candidate for visceral leishmaniasis. Clin Vaccine Immunol 18: 1118-1124.
13. Liew FY, (1989) Functional heterogeneity of CD4+ T cells in leishmaniasis. Immunol Today 10: 40-45.
14. Muller I, Pedrazzini T, Farrell JP, Louis J, (1989) T-cell responses and immunity to experimental infection with leishmania major. Annu Rev Immunol 7: 561-578.
15. Kedzierski L, (2010) Leishmaniasis Vaccine: Where are We Today? J Glob Infect Dis 2: 177-185.
16. Reiner SL, Locksley RM, (1995) The regulation of immunity to Leishmania major. Annu Rev Immunol 13: 151-177.
17. Sacks D, Noben-Trauth N, (2002) The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol 2: 845-858.
18. Scott P, Artis D, Uzonna J, Zaph C, (2004) The development of effector and memory T cells in cutaneous leishmaniasis: the implications for vaccine development. Immunol Rev 201: 318-338.
19. Webb JR, Campos-Neto A, Ovendale PJ, Martin TI, Stromberg EJ, et al. (1998) Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family. Infect Immun 66: 3279-3289.
20. Peters NC, Egen JG, Secundino N, Debrabant A, Kimblin N, et al. (2008) In vivo imaging reveals an essential role for neutrophils in leishmaniasis transmitted by sand flies. Science 321: 970-974.
21. Coler RN, Bertholet S, Moutaftsi M, Guderian JA, Windish HP, et al. (2011) Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS One 6: e16333.
22. Anderson RC, Fox CB, Dutill TS, Shaverdian N, Evers TL, et al. (2010) Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations. Colloids Surf B Biointerfaces 75: 123-132.
23. Kamhawi S, Belkaid Y, Modi G, Rowton E, Sacks D, (2000) Protection against cutaneous leishmaniasis resulting from bites of uninfected sand flies. Science 290: 1351-1354.
24. Nicolas L, Prina E, Lang T, Milon G, (2002) Real-time PCR for detection and quantitation of leishmania in mouse tissues. J Clin Microbiol 40: 1666-1669.
25. Oliveira F, Lawyer PG, Kamhawi S, Valenzuela JG, (2008) Immunity to distinct sand fly salivary proteins primes the anti-Leishmania immune response towards protection or exacerbation of disease. PLoS Negl Trop Dis 2: e226.
26. Coler RN, Skeiky YA, Bernards K, Greeson K, Carter D, et al. (2002) Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis. Infect Immun 70: 4215-4225.
27. Coler RN, Goto Y, Bogatzki L, Raman V, Reed SG, (2007) Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4+ T cells. Infect Immun 75: 4648-4654.
28. Chakravarty J, Kumar S, Trivedi S, Rai VK, Singh A, et al. (2011) A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis. Vaccine 29: 3531-3537.
29. Llanos-Cuentas A, Calderon W, Cruz M, Ashman JA, Alves FP, et al. (2010) A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with sodium stibogluconate for the treatment of mucosal leishmaniasis. Vaccine 28: 7427-7435.
30. Nascimento E, Fernandes DF, Vieira EP, Campos-Neto A, Ashman JA, et al. (2010) A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with meglumine antimoniate for the treatment of cutaneous leishmaniasis. Vaccine 28: 6581-6587.
31. Miret J, Nascimento E, Sampaio W, Franca JC, Fujiwara RT, et al. (2008) Evaluation of an immunochemotherapeutic protocol constituted of N-methyl meglumine antimoniate (Glucantime) and the recombinant Leish-110f+MPL-SE vaccine to treat canine visceral leishmaniasis. Vaccine 26: 1585-1594.
32. Trigo J, Abbehusen M, Netto EM, Nakatani M, Pedral-Sampaio G, et al. (2010) Treatment of canine visceral leishmaniasis by the vaccine Leish-111f+MPL-SE. Vaccine 28: 3333-3340.
33. Skeiky YA, Coler RN, Brannon M, Stromberg E, Greeson K, et al. (2002) Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant. Vaccine 20: 3292-3303.
34. Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, et al. (2007) Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 13: 843-850.